Jpmorgan Chase & CO Albireo Pharma, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$18.01 - $23.78 $23,106 - $30,509	1,283 Added 13.51%	10,781 $233,000
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $3,100 - $5,010	190 Added 2.04%	9,498 $183,000
Q2 2022 Aug 11, 2022	BUY	$18.54 - $37.29 $24,064 - $48,402	1,298 Added 16.2%	9,308 $186,000
Q1 2022 May 11, 2022	BUY	$23.94 - $33.74 $32,103 - $45,245	1,341 Added 20.11%	8,010 $239,000
Q4 2021 Feb 10, 2022	BUY	$21.19 - $31.29 $6,399 - $9,449	302 Added 4.74%	6,669 $156,000

Q3 2021 Nov 12, 2021	BUY	$27.36 - $35.98 $174,201 - $229,084	6,367 New	6,367 $199,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.